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What is Already Known about this Subject {#bcp13563-sec-0005}
========================================

Most drugs for neonates are prescribed off‐label and the evidence for use is limited due to a scarcity of clinical trials on efficacy, dosage and safety.Considerable variation is observed between Dutch NICUs both regarding the number of antibiotics and the total dosage.

What this Study Adds {#bcp13563-sec-0006}
====================

The prescription of nervous system and cardiovascular drugs is highly variable between NICUs. These differences become larger with decreasing postmenstrual age, although the proportion of off‐label prescriptions in relation to neonatal age decreased.Despite the new FDA and EMA drug legislation, many drugs are still used off‐label and the variability in drug prescriptions reflects the lack of evidence on drug use, especially in the smallest newborns.Consensus meetings on the treatment of common diseases and development of (inter)national guidelines should receive the highest priority.

Introduction {#bcp13563-sec-0007}
============

Infants in the neonatal intensive care unit (NICU) are exposed to a large number of drugs. Most drugs are off‐label for neonates and evidence for use in this population is sparse, due to a limited number of clinical trials on efficacy, dosage and safety [1](#bcp13563-bib-0001){ref-type="ref"}, [2](#bcp13563-bib-0002){ref-type="ref"}. These knowledge gaps are prone to large differences in interpretation of available evidence and will consequently be translated into different drug therapies described in local treatment protocols and neonatal practice.

Previous studies have described drug prescriptions during infancy, reporting a large proportion of off‐label drug use [2](#bcp13563-bib-0002){ref-type="ref"}, [3](#bcp13563-bib-0003){ref-type="ref"}, [4](#bcp13563-bib-0004){ref-type="ref"}, [5](#bcp13563-bib-0005){ref-type="ref"}, [6](#bcp13563-bib-0006){ref-type="ref"}, [7](#bcp13563-bib-0007){ref-type="ref"}. The proportion of off‐label prescribed drugs increases with decreasing age. Therefore, the most vulnerable paediatric group -- preterm infants -- has the highest exposure to drugs that are insufficiently documented [2](#bcp13563-bib-0002){ref-type="ref"}. In neonatal care, almost all patients are exposed to at least one off‐label or non‐approved drug during admission. Off‐label use of drugs has been associated with the risk of adverse drug reactions [8](#bcp13563-bib-0008){ref-type="ref"}. To improve paediatric drug therapy, new legislation was introduced more than a decade ago in the United States with the Pediatric Research Equity Act in 2003 [9](#bcp13563-bib-0009){ref-type="ref"}, the Food and Drug Administration Reauthorization Act of 2017 [10](#bcp13563-bib-0010){ref-type="ref"}, and in the European Union with the Paediatric Regulation in 2006 [11](#bcp13563-bib-0011){ref-type="ref"} to encourage paediatric drug research in the pre‐ and post‐marketing phase. However, these have not yet led to increased licensing [12](#bcp13563-bib-0012){ref-type="ref"}, [13](#bcp13563-bib-0013){ref-type="ref"}.

We aimed to investigate the differences in currently prescribed drugs between neonatal intensive care units (NICUs) in the Netherlands, and to study the off‐label proportions, as well as drug‐class and age‐related differences.

Methods {#bcp13563-sec-0008}
=======

Patients and setting {#bcp13563-sec-0009}
--------------------

In this retrospective cohort, all patients with an admission date between 1 September 2014 and 31 August 2015 to one of the four participating Dutch level III NICUs (Radboud University Medical Center Nijmegen, Maastricht University Medical Center Maastricht, Máxima Medical Center Veldhoven and Sophia Children\'s Hospital Rotterdam) were eligible for inclusion. The study was conducted according to Good Clinical Practice and the Declaration of Helsinki.

Definitions and drug classification {#bcp13563-sec-0010}
-----------------------------------

A prescription was defined as a patient for whom a specific drug was prescribed during admission to the NICU, regardless of how often it was prescribed and of the route of administration. Patient days were defined as the sum of treatment days of each drug during admission to the NICU, which was calculated per patient and as a total. All drugs were classified in accordance with the Anatomical Therapeutic Chemical (ATC) classification system.

The definition by Neubert *et al*. for "off‐label use" was applied, meaning 'all uses of a marketed drug not detailed in the summary of product characteristics (SmPC) including therapeutic indication, use in age‐subsets, appropriate strength (dosage), pharmaceutical form and route of administration' [14](#bcp13563-bib-0014){ref-type="ref"}. However, the on/off‐label status could be assessed only for the active substance in relation to age‐subsets, as information concerning dosage, route of administration, indication, drug preparation and formulation, could not be collected from all four hospitals. Therefore, on/off‐label status in relation to neonatal age (\<1 month after birth) was assessed according to the SmPC, which was consulted via the Dutch Medicines Evaluation Board (<http://www.cbg-meb.org>, accessed on 12 October 2017). The status of a drug was considered on‐label if an SmPC for that active substance describes an indication that includes infants below 1 month of age, which is also the case if the drug is indicated for children in general.

Data collection {#bcp13563-sec-0011}
---------------

All four hospitals prescribed drugs using a computerized physician order entry system. Patient characteristics and drug prescriptions were retrieved from the electronical medical records of each hospital. Data were collected on date of admittance, birth date, gestational age, birthweight, gender, survival, drugs administered, and date and duration of drug administration until death or discharge from the NICU. We excluded ATC class 'Q' of veterinary drugs. We also excluded electrolytes, total parenteral nutrition, Dutch national health care system vaccines, supportive dermatological products (not containing a drug), and contrast media. We followed the guidelines in the Reporting of Studies Conducted using Observational Routinely Collected Data (RECORD) statement to report our study [15](#bcp13563-bib-0015){ref-type="ref"}.

Data processing and statistical analysis {#bcp13563-sec-0012}
----------------------------------------

Data from the four NICUs were combined for the overall analyses of neonatal prescriptions. The prescription frequency was ranked, together with an analysis of the proportion of prescriptions that were off‐label in relation to neonatal age. For comparison of the NICU prescriptions, patients were classified into five different postmenstrual age groups at start of drug use, because gestational age groups would be confounded by drug use at a later postnatal age: \<26 weeks, 26--28 weeks, 28--32 weeks, 32--37 weeks and term neonates ≥37 weeks. Exposure to drugs was defined as either the absolute number of prescriptions or expressed per 1000 infants. Variability in prescribed drugs per ATC class between NICUs was quantified by calculating the range of total prescriptions per ATC class per 1000 patients between NICUs. This range was used to select the ATC classes for further investigation. All data were stored and analysed in SPSS Statistics version 21 (IBM, Armonk, NY, USA), using the non‐parametric Kruskal--Wallis test for continuous variables and Pearson\'s χ^2^ test for nominal variables, with a *P*‐value of \<0.05 for significance.

Treatment protocol comparison {#bcp13563-sec-0013}
-----------------------------

Four common indications for drug use in neonatal care were selected to compare the drugs and their suggested order as written in the treatment protocols of the four NICUs. This could give more insight into possible causes for differences in drug prescriptions. The selected indications were pain, intubation, convulsions and hypotension.

Results {#bcp13563-sec-0014}
=======

During the one‐year period, 1491 neonates were included in the study with a total of 32 182 patient days, and a median gestational age of 32^+5^ weeks (IQR: 29^+6^--37^+6^ weeks). The median birth weight of all neonates was 1865 g (IQR: 1253--3000 g), of which 14.5% had an extremely low birth weight (ELBW; \<1000 g). The median duration of admission to the NICU was 12 days (IQR: 5--32 days). Data on post menstrual age (PMA) at discharge was missing in six cases. Gestational age, birth weight, duration of admission to the NICU, and postmenstrual age at discharge were all significantly different between the four hospitals (Table [1](#bcp13563-tbl-0001){ref-type="table-wrap"}).

###### 

Baseline characteristics of hospitalized neonates in four different NICUs in the Netherlands

                                                 NICU 1                    NICU 2                    NICU 3                    NICU 4                    *p* value                                        Total/overall
  ---------------------------------------------- ------------------------- ------------------------- ------------------------- ------------------------- ------------------------------------------------ -------------------------
  **Number of beds**                             18                        15                        13                        31                                                                         
  **Number of patients given drugs**             314                       353                       223                       601                                                                        1491
  **Male gender (%)**                            60                        59                        55                        58                        0.615[a](#bcp13563-note-0002){ref-type="fn"}     58
  **Gestational age (weeks** ^**+days**^ **)**   31^+5^ (29^+2^--35^+5^)   33^+2^ (30^+2^--38^+0^)   34^+6^ (30^+5^--38^+3^)   32^+2^ (29^+4^--37^+5^)   \<0.001[b](#bcp13563-note-0003){ref-type="fn"}   32^+5^ (29^+6^--37^+6^)
  **\<26 weeks (%)**                             17 (5.4)                  15 (4.3)                  8 (3.6)                   39 (6.5)                  0.001[c](#bcp13563-note-0004){ref-type="fn"}     79 (5.3)
  **26--28 weeks (%)**                           33 (10.5)                 32 (9.1)                  15 (6.7)                  59 (9.8)                                                                   139 (9.3)
  **28--32 weeks (%)**                           112 (35.7)                96 (27.3)                 51 (22.9)                 185 (30.8)                                                                 444 (29.8)
  **32--37 weeks (%)**                           82 (26.1)                 88 (25.0)                 53 (23.8)                 139 (23.2)                                                                 362 (24.3)
  **≥ 37 weeks (%)**                             70 (22.3)                 121 (34.4)                96 (43.0)                 178 (29.6)                                                                 465 (31.2)
  **Birth weight (g)**                           1695 (1228--2613)         2012 (1350--3091)         2100 (1370--3120)         1800 (1200--2970)         0.007[b](#bcp13563-note-0003){ref-type="fn"}     1865 (1253--3000)
  **ELBW (%)**                                   48 (15.3)                 51 (14.4)                 22 (9.9)                  95 (15.8)                 0.214[c](#bcp13563-note-0004){ref-type="fn"}     216 (14.5)
  **Number of days at NICU**                     24 (8--47)                12 (6--30)                12 (5--25)                7 (4--17)                 \<0.001[b](#bcp13563-note-0003){ref-type="fn"}   12 (5--32)
  **PMA at discharge**                           37^+2^ (35^+4^--39^+6^)   36^+6^ (33^+0^--40^+3^)   38^+1^ (35^+0^--40^+5^)   35^+0^ (32^+1^--39^+3^)   \<0.001[b](#bcp13563-note-0003){ref-type="fn"}   36^+5^ (33^+2^--40^+0^)
  **Total patient days**                         9789                      7769                      4716                      9908                                                                       32 182
  **Total prescriptions**                        2216                      3371                      1143                      4165                                                                       10 895
  **Drugs per patient**                          5 (3--10)                 7 (4--14)                 4 (2--6)                  5 (3--8)                  \<0.001[b](#bcp13563-note-0003){ref-type="fn"}   5 (3--10)
  **Patient days on drugs**                      28 (12--80)               36 (15--98)               18 (7--52)                13 (6--43)                \<0.001[b](#bcp13563-note-0003){ref-type="fn"}   21 (8--71)
  **% OL in relation to neonatal age**           21                        29                        11                        23                        \<0.001[b](#bcp13563-note-0003){ref-type="fn"}   23

Data presented as median (IQR).

χ^2^ test

Kruskal--Wallis one‐way analysis

χ^2^ for distributions in all strata of gestational ages in four NICUs

Overall prescription of drugs and off‐label use in relation to neonatal age {#bcp13563-sec-0015}
---------------------------------------------------------------------------

In total, 181 different drugs were prescribed 10 895 times, of which 23% was off‐label in relation to neonatal age (see [Supporting Information File S1](#bcp13563-supitem-0001){ref-type="supplementary-material"} for on‐label age‐range in SmPC). The proportion of off‐label prescriptions in relation to neonatal age increased with PMA at start of drug therapy: 19% for infants with PMA at start below 32 weeks, 26% for infants with PMA between 32 and 37 weeks, and 29% above 37 weeks PMA. During admission, 54% of the neonates were exposed to at least one off‐label drug. The median number of prescribed drugs per patient was five (IQR: 3--10). This was significantly different between hospitals varying from a median of four to seven drugs per patient.

The ATC class with the most frequently prescribed drugs was anti‐infective drugs with a total of 3161 prescriptions (29%), of which 4% was off‐label in relation to neonatal age (Figure [1](#bcp13563-fig-0001){ref-type="fig"}, Table [2](#bcp13563-tbl-0002){ref-type="table-wrap"}). The second largest ATC class was the nervous system drugs with 2500 prescriptions (23%) of which 31% was off‐label in relation to neonatal age. The drug class of blood and blood‐forming organs was the third largest with 1386 prescriptions (13%). However, this result was confounded since 54% of these prescriptions concerned phytomenadione prescribed as supplementary vitamin instead of the labelled indication as an antidote to anticoagulant drugs of the coumarin type. The large proportion of 28% off‐label prescriptions was caused by heparin for 86%, which was indicated for arterial catheter patency. Alimentary tract and metabolism drugs were fourth largest with 1327 prescriptions (12%), 17% of which was off‐label in relation to neonatal age. Cardiovascular drugs were the fifth largest class with 958 prescriptions (9%), of which 30% was off‐label in relation to neonatal age, for 84% due to dopamine and noradrenaline. The sixth largest ATC class was the respiratory drugs with 36% off‐label prescriptions, of which 76% was accounted for by xylometazoline and doxapram.

![Total number of prescriptions and proportion off‐label in each Anatomical Therapeutic Chemical (ATC) groupIn total, 10 895 prescriptions of 181 different drugs were retrieved, of which 23% was off‐label in relation to neonatal age. \* Range of total prescriptions per ATC class per 1000 patients between NICUs.](BCP-84-1313-g001){#bcp13563-fig-0001}

###### 

Most frequently prescribed drugs per 1000 neonates

  No       All drugs                      Prescriptions   No   Off‐label drugs in relation to neonatal age   Prescriptions
  -------- ------------------------------ --------------- ---- --------------------------------------------- ---------------
  **1**    Phytomenadione                 668             1    Heparin                                       219
  **2**    Cholecalciferol                521             2    Fentanyl                                      193
  **3**    Caffeine                       480             3    Propofol                                      117
  **4**    Amoxicillin                    375             4    Dopamine                                      109
  **5**    Gentamicin                     375             5    Phenobarbital                                 91
  **6**    Tobramycin                     302             6    Hydrocortisone                                79
  **7**    Benzylpenicillin               287             7    Xylometazoline                                68
  **8**    Paracetamol                    273             8    Miconazole                                    66
  **9**    Surfactant                     251             9    Phenylephrine + Tropicamide                   57
  **10**   Morphine                       247             10   Norepinephrine                                53
  **11**   Heparin                        219             11   Insulin                                       50
  **12**   Fentanyl                       193             12   Meropenem                                     43
  **13**   Amoxicillin+ clavulanic acid   165             13   Dexamethasone                                 42
  **14**   Midazolam                      148             14   Doxapram                                      42
  **15**   Atropine                       137             15   Phenylephrine                                 38
  **16**   Flucloxacillin                 133             16   Chloralhydrate                                30
  **17**   Rocuronium                     133             17   Ranitidine                                    27
  **18**   Vancomycin                     132             18   Levetiracetam                                 25
  **19**   Furosemide                     130             19   Cefazolin                                     15
  **20**   Propofol                       117             20   Cisatracurium                                 15
  **21**   Dopamine                       109             21   Ursodeoxycholic acid                          15
  **22**   Ceftazidime                    95              22   Antitrombin                                   14
  **23**   Phenobarbital                  91              23   Esketamine                                    14
  **24**   Ibuprofen                      91              24   Tocopherol                                    13
  **25**   Nystatin                       81              25   Retinol                                       11
  **26**   Hydrochlorothiazide            80              26   Trimethoprim                                  11
  **27**   Spironolactone                 80              27   Levomepromazine                               10
  **28**   Hydrocortisone                 79              28   Sildenafil                                    10
  **29**   Dobutamine                     70              29   Dornase                                       9
  **30**   Xylometazoline                 68              30   Lidocaine                                     9

Total of 10 985 prescriptions for 1491 patients. The number (No) indicates the ranking of prescribed drugs per 1000 patients

Table [2](#bcp13563-tbl-0002){ref-type="table-wrap"} provides the most prescribed drugs overall and off‐label in all NICUs, which overall were, in rank order, phytomenadione, cholecalciferol, caffeine, amoxicillin, gentamicin, tobramycin, benzylpenicillin, paracetamol, surfactant and morphine. Of these, none are off‐label in relation to neonatal age.

Differences in drug use between NICUs {#bcp13563-sec-0016}
-------------------------------------

The largest differences between NICUs were found for nervous system drugs, with total prescriptions between NICUs ranging 919--2278 per 1000 patients followed by 554--1465 for blood and blood‐forming organs, and 238--952 for cardiovascular system drugs, respectively (Figure [1](#bcp13563-fig-0001){ref-type="fig"}). As 86% of the range of prescribed drugs from blood and blood‐forming organs is caused by heparin and phytomenadione, cardiovascular and nervous system drugs were considered most interesting for a more extensive comparison (Figure [2](#bcp13563-fig-0002){ref-type="fig"}).

![Range of prescriptions per drug per 1000 patients between NICUs in descending order. The top 35 drugs are listed in descending order of the largest difference between minimum and maximum prescriptions.](BCP-84-1313-g002){#bcp13563-fig-0002}

Cardiovascular drug prescriptions differed between the four NICUs (Table [3](#bcp13563-tbl-0003){ref-type="table-wrap"}), and with PMA (Figure [3](#bcp13563-fig-0003){ref-type="fig"}A). Table [3](#bcp13563-tbl-0003){ref-type="table-wrap"} shows that the prescription of cardiovascular drugs varied from none to six different agents between the different NICUs in infants with PMA below 26 weeks. Dopamine exposure for those neonates was high in two NICUs, where another NICU showed larger variety of other haemodynamic agonists for these preterm infants, i.e. dobutamine and adrenaline. Furthermore, nervous system drugs showed large variety (Figure [3](#bcp13563-fig-0003){ref-type="fig"}B, Table [4](#bcp13563-tbl-0004){ref-type="table-wrap"}). Interesting differences included the variable use of propofol, levetiracetam and diuretics between NICUs for all PMAs. Prescriptions of paracetamol and phenobarbital were particularly different in the youngest infants.

###### 

Cardiovascular drug prescriptions according to PMA (per 1000 neonates per PMA group)

                        **NICU 1**   NICU 2                NICU 3       NICU 4                                                                         
  --------------------- ------------ --------------------- ------------ --------------------- --------------------- --------------------- ------------ -----
  **\<26**              Dopamine     353                   Dopamine     467                                                               Dobutamine   231
  Norepinephrine        59                                                                                          Dopamine              154          
                                                                                                                    Epinephrine           77           
                                                                                                                    Hydrochlorothiazide   77           
                                                                                                                    Spironolactone        77           
                                                                                                                    Furosemide            26           
  **26 \< 28**          Dopamine     273                   Dopamine     156                   Furosemide            67                    Furosemide   339
  Furosemide            242          Furosemide            125                                                      Dobutamine            254          
  Hydrochlorothiazide   91           Norepinephrine        63                                                       Hydrochlorothiazide   237          
  Spironolactone        91           Epinephrine           31                                                       Spironolactone        237          
  Dobutamine            61           Dobutamine            31                                                       Dopamine              153          
  Epinephrine           30           Milrinone             31                                                       Epinephrine           85           
  **28 \< 32**          Furosemide   107                   Furosemide   156                   Furosemide            157                   Furosemide   205
  Dopamine              63           Dopamine              146          Hydrochlorothiazide   78                    Hydrochlorothiazide   184          
  Epinephrine           27           Norepinephrine        94           Spironolactone        78                    Spironolactone        184          
  Norepinephrine        27           Hydrochlorothiazide   42                                                       Dobutamine            114          
  Hydrochlorothiazide   18           Spironolactone        42                                                       Dopamine              97           
  Spironolactone        18           Dobutamine            31                                                       Epinephrine           92           
  **32 \< 37**          Furosemide   98                    Dopamine     170                   Hydrochlorothiazide   113                   Furosemide   151
  Dopamine              85           Norepinephrine        148          Spironolactone        113                   Hydrochlorothiazide   122          
  Hydrochlorothiazide   85           Furosemide            125          Furosemide            75                    Spironolactone        122          
  Spironolactone        85           Hydrochlorothiazide   34           Metoprolol            19                    Dobutamine            94           
  Dobutamine            24           Spironolactone        34                                                       Epinephrine           58           
  Norepinephrine        24           Epinephrine           23                                                       Dopamine              58           
  **≥37**               Dopamine     100                   Dopamine     289                   Furosemide            63                    Dobutamine   129
  Hydrochlorothiazide   71           Norepinephrine        248          Hydrochlorothiazide   52                    Epinephrine           84           
  Spironolactone        71           Furosemide            215          Spironolactone        52                    Dopamine              56           
  Norepinephrine        57           Milrinone             149          Digoxine              21                    Furosemide            51           
  Epinephrine           43           Alprostadil           116          Propranolol           10                    Alprostadil           45           
  Alprostadil           29           Dobutamine            99                                                       Hydrochlorothiazide   39           

The top five prescribed cardiovascular drugs are shown for every PMA group.

NICU, neonatal intensive care unit; PMA, postmenstrual age

![Exposure of preterm neonates in four NICUs to (A) cardiovascular and (B) nervous system drugs at different PMAs. The number of cardiovascular drug prescriptions is expressed per 1000 patients in each PMA group. NICU, neonatal intensive care unit; PMA, postmenstrual age](BCP-84-1313-g003){#bcp13563-fig-0003}

###### 

Nervous system drug prescriptions according to PMA (per 1000 neonates per PMA group)

                 **NICU1**        **NICU2**   **NICU3**        **NICU4**                                           
  -------------- ---------------- ----------- ---------------- ----------- ----------------- ----- --------------- -----
  **\<26**       Caffeine         647         Caffeine         667         Caffeine          750   Caffeine        923
                 Fentanyl         529         Morphine         400         Paracetamol       125   Propofol        462
                 Morphine         176         Fentanyl         333                                 Morphine        231
                 Paracetamol      114         Midazolam        133                                 Fentanyl        103
                                              Paracetamol      25                                  Midazolam       77
                                                                                                   Phenobarbital   51
  **26 \< 28**   Caffeine         970         Caffeine         844         Caffeine          800   Caffeine        864
                 Fentanyl         394         Fentanyl         469         Paracetamol       267   Propofol        492
                 Paracetamol      333         Morphine         281         Fentanyl          200   Morphine        305
                 Morphine         273         Midazolam        156         Morphine          67    Fentanyl        186
                 Phenobarbital    91          Paracetamol      125         Phenobarbital     67    Midazolam       119
                 Midazolam        61          Phenobarbital    94          Midazolam         67    Phenobarbital   102
  **28 \< 32**   Caffeine         857         Caffeine         927         Caffeine          902   Caffeine        724
                 Fentanyl         304         Fentanyl         317         Paracetamol       78    Propofol        314
                 Paracetamol      259         Morphine         238         Fentanyl          59    Morphine        195
                 Morphine         170         Paracetamol      222         Methadone         59    Fentanyl        108
                 Propofol         27          Midazolam        95          Phenobarbital     39    Midazolam       81
                 Midazolam        18          Phenobarbital    63          Midazolam         39    Phenobarbital   49
  **32 \< 37**   Paracetamol      427         Morphine         364         Caffeine          566   Caffeine        403
                 Caffeine         378         Paracetamol      352         Paracetamol       226   Morphine        266
                 Morphine         134         Caffeine         341         Etomidate         57    Propofol        252
                 Fentanyl         122         Fentanyl         307         Fentanyl          57    Paracetamol     209
                 Phenobarbital    98          Midazolam        182         Midazolam         38    Fentanyl        173
                 Propofol         98          Chloralhydrate   80          Dexmedetomidine   19    Midazolam       165
  **\>37**       Paracetamol      557         Morphine         686         Paracetamol       396   Paracetamol     309
                 Morphine         257         Paracetamol      512         Phenobarbital     73    Midazolam       281
                 Phenobarbital    157         Midazolam        504         Caffeine          63    Morphine        253
                 Midazolam        157         Fentanyl         388         Fentanyl          31    Phenobarbital   185
                 Propofol         114         Phenobarbital    231         Midazolam         31    Levetiracetam   129
                 Chloralhydrate   100         Chloralhydrate   149         Morphine          21    Propofol        79

The top five prescribed nervous system drugs are shown for every PMA group.

NICU, neonatal intensive care unit; PMA, postmenstrual age

Treatment protocol comparison {#bcp13563-sec-0017}
-----------------------------

Table [5](#bcp13563-tbl-0005){ref-type="table-wrap"} gives an overview of the drugs and the order in which they should be prescribed according to the local treatment protocols in the different NICUs for the four selected indications per gestational age groups.

###### 

Order of drugs in treatment protocols concerning four major care indications in the four NICUs

                    No                                                                NICU1                   No                          NICU2           No                                                      NICU3           No                         NICU4
  ----------------- ----------------------------------------------------------------- ----------------------- --------------------------- --------------- ------------------------------------------------------- --------------- -------------------------- ---------------
  **Pain**                                                                            Paracetamol                                         EMLA                                                                    Paracetamol                                Fentanyl
                    EMLA                                                                                      Lidocaine                                   Lidocaine                                                               Morphine                   
                    Morphine                                                                                  Morphine                                    Fentanyl                                                                Midazolam                  
                    Lidocaine                                                                                 Fentanyl                                    Methadone                                                               Paracetamol                
                    Fentanyl                                                                                  Paracetamol                                 Morphine                                                                                           
                                                                                                              Midazolam                                   Lorazepam                                                                                          
                                                                                                              Levomepromazine                                                                                                                                
                                                                                                              Esketamine                                                                                                                                     
  **Hypotension**   1                                                                 Dopamine                1                           Dopamine        1                                                       Dopamine                                   
  2                 Dobutamine/Norepinephrine                                         2                       Dobutamine/Norepinephrine   1               Dobutamine                                                                                         
  3                 Hydrocortisone                                                    3                       Dexamethasone               1               Norepinephrine                                                                                     
                                                                                      3                       Epinephrine                 1               Epinephrine                                                                                        
                                                                                      3                       Milrinone                   2               Hydrocortisone                                                                                     
                                                                                      3                       Hydrocortisone              2               Methylene blue[b](#bcp13563-note-0013){ref-type="fn"}                                              
                                                                                                                                          2               Naloxone[b](#bcp13563-note-0013){ref-type="fn"}                                                    
  **Intubation**    1                                                                 Atropine (\<32 weeks)   1                           Atropine        1                                                       Atropine        1                          Propofol
  1                 Fentanyl (\<32 weeks)                                             1                       Fentanyl/morphine           1               Fentanyl/morphine                                                                                  
  1                 Rocuronium (\<32 weeks)                                           1                       Rocuronium/vecuronium       1               Rocuronium/etomidate                                                                               
  2                 Propofol (\>32 weeks)                                                                                                                                                                                                                    
  **Convulsions**   1                                                                 Phenobarbital           1                           Phenobarbital   1                                                       Phenobarbital   1                          Phenobarbital
  2                 Levetiracetam                                                     2                       Midazolam (+ pyridoxine)    2               Midazolam                                               2               Midazolam (+ pyridoxine)   
  3                 Lidocaine                                                         3                       Lidocaine                   3               Lidocaine                                               3               Lidocaine                  
  4                 Midazolam[a](#bcp13563-note-0012){ref-type="fn"} (+ pyridoxine)   4                       Levetiracetam               4               Pyridoxine                                              4               Levetiracetam              
  5                 Clonazepam                                                        5                       Pyridoxine                  5               Thiopental                                              5               Pyridoxine                 
  6                 Thiopental                                                                                                                                                                                    5               Clonazepam                 

The number (No) indicates the order in which drugs should be prescribed for treatment of each indication. If the same number has been used multiple times for one indication in one NICU, this means that their preference is equal, meaning that the attending physician is free to select one of the suggestions. One drug may be prescribed or a combination of drugs simultaneously. The absence of a number concerning pain treatment indicates none of the NICUs suggest a certain order in the drugs to be prescribed for pain treatment.

NICU, neonatal intensive care unit

Preferably avoid midazolam use for premature born infants

Experimental drugs

Discussion {#bcp13563-sec-0018}
==========

We evaluated drug prescriptions between NICUs for a period of one year and found that a considerable percentage of the drugs are still used off‐label and that large differences exist in drug prescriptions between the four NICUs. The largest variability was found for drug classes with the highest proportion of off‐label drugs in relation to neonatal age, i.e. cardiovascular and nervous system drugs. These differences became larger with decreasing PMA, although the proportion of off‐label prescriptions became smaller. Despite the new FDA and EMA drug legislations, many drugs are still used off‐label and the variability in drugs prescriptions reflects the lack of evidence on drug use, especially in the smallest newborns.

Prescribed drugs {#bcp13563-sec-0019}
----------------

Of almost 11 000 drug prescriptions for neonates, 23% was off‐label in relation to neonatal age. Comparable proportions of off‐label prescriptions in relation to neonatal age were found in the last decade by Neubert *et al*. with 38% in Germany [16](#bcp13563-bib-0016){ref-type="ref"}, Hsieh *et al*. with 35% in the USA [1](#bcp13563-bib-0001){ref-type="ref"}, and Cuzzolin *et al*. with 34% in Italy [17](#bcp13563-bib-0017){ref-type="ref"}. A comforting finding was that the proportion of off‐label prescriptions in relation to neonatal age increased with PMA at start of drug therapy. Therefore, the most vulnerable infants with the lowest PMA were exposed to fewer off‐label drugs than infants at higher PMA. This might reflect the cautiousness of clinicians in treating the most vulnerable patients. Dell\'Aera *et al*. and Avenel *et al*. also found a higher prevalence of off‐label prescriptions within the full‐term neonates compared to the preterms [5](#bcp13563-bib-0005){ref-type="ref"}, [18](#bcp13563-bib-0018){ref-type="ref"}.

Also comforting was the small proportion of off‐label drug prescriptions in relation to neonatal age (4%) in the largest drug class of anti‐infective drugs. On the other hand, the second largest class concerned the nervous system drugs, of which 31% was off‐label in relation to neonatal age. These findings are in agreement with those of Cuzzolin *et al*. and Neubert *et al*. who also found that anti‐infective drugs were the largest ATC class prescribed with a proportion off‐label in relation to neonatal age of 24% and 11%, respectively [16](#bcp13563-bib-0016){ref-type="ref"}, [17](#bcp13563-bib-0017){ref-type="ref"}. For nervous system drugs, these studies found a proportion of 67% and 56% of off‐label prescriptions in relation to neonatal age, which is comparable with our results.

Nevertheless, off‐label drug use does not necessarily imply inadequate drug use, although this is generally suggested [19](#bcp13563-bib-0019){ref-type="ref"}. Instead of referring to the label, adequate drug use should be based on the level of evidence, with an expert interpretation. Consequently, several sources have been developed which are periodically updated and released, such as the *British National Formulary*, *Pediatric Dosages* by Lexicomp, *Pediatric Injectable Drugs,* and *Micromedex*. Ceelie *et al*. reported on large differences between four commonly used paediatric drug formularies, which indicates the challenges in the availability and reliability of paediatric drug dosing guidelines in present drug formularies [20](#bcp13563-bib-0020){ref-type="ref"}. Recently, in the Netherlands a continuously updated online paediatric formulary has been released -- the Dutch Paediatric Formulary [21](#bcp13563-bib-0021){ref-type="ref"}. Despite the valuable interpretation regarding dosages and safe drug use, the sources mentioned above do not suggest which drug to choose for certain indications and therefore do not help to reduce the differences in prescriptions between physicians and hospitals.

Comparing NICUs {#bcp13563-sec-0020}
---------------

Large differences between NICUs were found in neonatal drug use. Drug classes with a high proportion of off‐label drug prescriptions in relation to neonatal age showed the largest differences between NICUs, i.e. cardiovascular and nervous system drugs. Also, these ATC classes, together with ATC class blood and blood‐forming organs, showed the largest range of total prescriptions per ATC class per 1000 patients between NICUs. As the high rank of blood and blood‐forming organs was driven by heparin and phytomenadione alone, this class was of limited interest for further comparison.

The large differences among cardiovascular drugs strengthen the alarming message of a severe lack in paediatric documentation, which has been reported by Bajcetic *et al*. [22](#bcp13563-bib-0022){ref-type="ref"} and Pasquali *et al*. [23](#bcp13563-bib-0023){ref-type="ref"}. Nervous system drugs also showed large variability, which may be a reflection of the variation in drugs mentioned in pain treatment protocols of these four NICUs. This may be explained by the worldwide discussion on the neurodevelopmental safety of nervous system drugs such as opioids, paracetamol and benzodiazepines in the preterm brain [24](#bcp13563-bib-0024){ref-type="ref"}. A comparable discussion accounts for the choice of premedication for intubation [25](#bcp13563-bib-0025){ref-type="ref"}, [26](#bcp13563-bib-0026){ref-type="ref"}, [27](#bcp13563-bib-0027){ref-type="ref"}. This can be recognized in treatment protocols in our study, choosing either an opioid with a muscle relaxant, or propofol. Mehler *et al*. studied analgesic and sedative drug use in very low birth weight infants in German NICUs and reported large differences, as well as many changes over time in analgesic and sedative treatment [28](#bcp13563-bib-0028){ref-type="ref"}. On the other hand, the treatment protocol of neonatal convulsions showed less differences between NICUs, which seems to be the result of an existing national guideline [29](#bcp13563-bib-0029){ref-type="ref"}. Even though all mentioned drugs in the guideline were off‐label for treatment of convulsions in neonates, this publicly accessible expert opinion appears to reduce different interpretations of sparse evidence.

Liem *et al*. reported a comparable approach for antibiotic drugs alone and found considerable variation between Dutch NICUs in the number of different antibiotics used and in the total dosage of antibiotics [30](#bcp13563-bib-0030){ref-type="ref"}. This heterogeneity indicates that empirical antibiotic treatment varies among NICUs and there are currently no consensus guidelines regarding the choice of empirical antibiotics.

Although all four participating NICUs were level 3, considerable differences were found in the general descriptives between the NICUs; i.e. duration of admission, gestational ages and specific treatments (surgery, extracorporeal membrane oxygenation). These may partly explain the large variability in prescribed drugs between NICUs. Another cause for differences in drug use concerns the steps by which new evidence is adapted to clinical care, which may depend on local expert opinions.

Our multicentre comparison of drug use in NICUs provides a unique view of neonatal pharmacology in practice but is limited by some assumptions. First, our data did not allow comparison of NICUs with respect to drug dosages, routes of administration, specific products or preparation of drugs for administration. Apart from judging whether a drug is registered for use in neonatal age, each of these items could also have been related to the label if the data were available. Second, since practically all drugs were first labelled for an adult indication, their ATC code was often incorrect with respect to their use in current neonatal practice. Even for drugs where the neonatal indication has been added to the label, their ATC code remains as primarily marketed. This concerns, for example, sildenafil, ibuprofen, caffeine and phytomenadione. Third, differences in local decision‐making practice determines treatments and drug use. In a smaller NICU it may be easier to reach consensus than in a larger NICU. Fourth, data was retrospectively collected from different prospective electronic health record systems, which may have caused some differences in definitions used for data output. Fifth, our findings from a single country cohort cannot easily be compared to other countries or reports, as the content of the SmPCs may be different between countries, and various definitions for off‐label status have been used, which has also been shown by Aronson *et al*. [31](#bcp13563-bib-0031){ref-type="ref"}. Sixth, if the SmPC mentioned an indication for infants in general without mentioning an age range, this was considered to also include neonates and therefore on‐label in relation to neonatal age (see [Supporting Information File S1](#bcp13563-supitem-0001){ref-type="supplementary-material"}). Nevertheless, physicians would not feel safe to prescribe these drugs in clinical practice based on this information, knowing that a general dosage for infants is not optimal and safe for (preterm) neonates. However, if these drugs, with an on‐label status for infants without mentioning an age range, were to be considered off‐label in relation to neonatal age instead, the overall proportion of off‐label prescriptions in our cohort increases from 23% to 41%. This is mainly due to changes in the ATC groups; cardiovascular drugs (from 30% to 94% off‐label), anti‐infectives (from 4% to 24% off‐label), and nervous system drugs (from 31% to 46% off‐label). In addition, an indication and dosage for neonates in the SmPC rarely differentiates for gestational age. As the definition of a 'neonate' is limited to a newborn infant during its first 30 days of life, without referring to a certain gestational age, we considered neonates to be term as well preterm newborn infants. Nevertheless, on‐label in relation to neonatal age should not necessarily mean on‐label for all gestational ages.

Future suggestions {#bcp13563-sec-0021}
------------------

Our study shows that there is great variability in the drug prescriptions for neonates in NICUs. Little consensus has been reached on these drugs, and therefore expert interpretation of current evidence and future research should be prioritized. New investigator‐initiated research is urgently required as there is little benefit to pharmaceutical companies in incorporating new findings in paediatrics, which has led to few drug‐labelling changes made under paediatric legislation, including neonates [12](#bcp13563-bib-0012){ref-type="ref"}. Nevertheless, pharmacological trials involving neonates deal with multiple challenges. Appropriate dosing is hampered by the rapid physiological changes occurring at this stage of development. The selection of proper end‐points and biomarkers is complicated by the limited knowledge of the pathophysiology of the specific diseases of infancy. Coppini *et al*. have addressed possible perspectives to stimulate research in neonates and infants [32](#bcp13563-bib-0032){ref-type="ref"}. Furthermore, as evidence on pharmacological treatment of neonates remains thin, more (inter)national guidelines on treatment of common indications should be published, following the successful example of the guideline for neonatal convulsions.

Conclusion {#bcp13563-sec-0022}
==========

We showed that drugs used for neonatal care differed importantly between four Dutch level 3 NICUs. Our findings form a valuable contribution to the several pooled prescription data analyses of multiple NICUs that have been reported. The drug classes with the highest proportion of off‐label drugs in relation to neonatal age showed the largest differences between NICUs, i.e. cardiovascular and nervous system drugs. We believe that drug research in neonates should have high priority to ensure the use of safe and appropriate drug therapy in newborns.
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